Medical Hypotheses
Volume 55, Issue 5 , Pages 386-403 , November 2000

Up-regulation of endothelial nitric oxide activity as a central strategy for prevention of ischemic stroke – Just say NO to stroke!

Received 24 November 1999 ,Accepted 6 January 2000.

References 

    REFERENCES
  1. Faraci FM, Brian JEJ. Nitric oxide and the cerebral circulation. Stroke. 1994;25:692–703
  2. Luscher TF, Noll G. Endothelial function as an end-point in interventional trials: concepts, methods and current data. J Hypertens. 1996;14:S111–S119
  3. Freedman JE, Loscalzo J. Endothelial dysfunction and atherothrombotic occlusive disease. Drugs. 1997;54:41–49
  4. Nishimura H, Rosenblum WI, Nelson GH, Boynton S. Agents that modify EDRF formation alter antiplatelet properties of brain arteriolar endothelium in vivo. Am J Physiol. 1991;261:H15–H21
  5. Tagami M, Ikeda K, Nara Y. Detailed examination of vascular lesions triggered by an inhibitor of endothelium-derived relaxing factor. Lab Invest. 1995;72:174–182
  6. Hayakawa H, Raij L. The link among nitric oxide synthase activity, endothelial function and aortic and ventricular hypertrophy in hypertension. Hypertension. 1997;29:235–241
  7. Fernandez N, Garcia JL, Garcia-Villalon AL, Monge L, Gomez B, Dieguez G. Cerebral blood flow and cerebrovascular reactivity after inhibition of nitric oxide synthesis in conscious goats. Br J Pharmacol. 1993;110:428–434
  8. Huang Z, Huang PL, Ma J. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J Cereb Blood Flow Metab. 1996;16:981–987
  9. Bolanos JP, Almeida A. Roles of nitric oxide in brain hypoxia-ischemia. Biochim Biophys Acta. 1999;1411:415–436
  10. Gidday JM, Shah AR, Maceren RG. Nitric oxide mediates cerebral ischemic tolerance in a neonatal rat model of hypoxic preconditioning. J Cereb Blood Flow Metab. 1999;19:331–340
  11. Kannel WB, Wolf PA, Verter J, McNamara PM. Epidemiologic assessment of the role of blood pressure in stroke.The Framingham study. JAMA. 1970;214:301–310
  12. Tanaka H, Ueda Y, Hayashi M. Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. Stroke. 1982;13:62–73
  13. Welin L, Svardsudd K, Wilhelmsen L, Larsson B.,Tibblin G. Analysis of risk factors for stroke in a cohort of men born in 1913. N Engl J Med. 1987;317:521–526
  14. Elkind MS, Sacco RL. Stroke risk factors and stroke prevention. Semin Neurol. 1998;18:429–440
  15. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87:1468–1474
  16. Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, Cannon RO. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation. 1995;91:1732–1738
  17. Taddei S, Salvetti A. Pathogenetic factors in hypertension. Endothelial factors. Clin Exp Hypertens. 1996;18:323–335
  18. Vanhoutte PM. Endothelial dysfunction in hypertension. J Hypertens. 1996;14:S83–S93
  19. Cardillo C, Kilcoyne CM, Quyyumi AA, Cannon RO, Panza JA. Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilation in patients with essential hypertension. Circulation. 1998;97:851–856
  20. Calver A, Collier J, Moncada S, Vallance P. Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens. 1992;10:1025–1031
  21. Taddei S, Virdis A, Mattei P. Hypertension causes premature aging of endothelial function in humans. Hypertension. 1997;29:736–743
  22. Luscher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension. 1986;8:344–348
  23. Luscher TF, Raij L, Vanhoutte PM. Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension. 1987;9:157–163
  24. Heistad DD, Mayhan WG, Coyle P, Baumbach GL. Impaired dilatation of cerebral arterioles in chronic hypertension. Blood Vessels. 1990;27:258–262
  25. Mayhan WG. Impairment of endothelium-dependent dilatation of basilar artery during chronic hypertension. Am J Physiol. 1990;259:H1455–H1462
  26. Volpe M, Iaccarino G, Vecchione C. Association and cosegregation of stroke with impaired endothelium-dependent vasorelaxation in stroke prone, spontaneously hypertensive rats. J Clin Invest. 1996;98:256–261
  27. Mayhan WG. Role of prostaglandin H2-thromboxane A2 in responses of cerebral arterioles during chronic hypertension. Am J Physiol. 1992;262:H539–H543
  28. Ge T, Hughes H, Junquero DC, Wu KK, Vanhoutte PM, Boulanger CM. Endothelium-dependent contractions are associated with both augmented expression of prostaglandin H synthase-1 and hypersensitivity to prostaglandin H2 in the SHR aorta. Circ Res. 1995;76:1003–1010
  29. Nava E, Farre AL, Moreno C. Alterations to the nitric oxide pathway in the spontaneously hypertensive rat. J Hypertens. 1998;16:609–615
  30. Grunfeld S, Hamilton CA, Mesaros S. Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. Hypertension. 1995;26:854–857
  31. Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA. Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension. 1999;33:1353–1358
  32. Taddei S, Virdis A, Ghiadoni L, Salvetti A. Endothelial dysfunction in hypertension: fact or fancy?. J Cardiovasc Pharmacol. 1998;32:S41–S47
  33. Novosel D, Lang MG, Noll G, Luscher TF. Endothelial dysfunction in aorta of the spontaneously hypertensive, stroke-prone rat: effects of therapy with verapamil and trandolapril alone and in combination. J Cardiovasc Pharmacol. 1994;24:979–985
  34. Bennett MA, Hillier C, Thurston H. Endothelium-dependent relaxation in resistance arteries from spontaneously hypertensive rats: effect of long-term treatment with perindopril, quinapril, hydralazine or amlodipine. J Hypertens. 1996;14:389–397
  35. Rodrigo E, Maeso R, Munoz-Garcia R. Endothelial dysfunction in spontaneously hypertensive rats: consequences of chronic treatment with losartan or captopril. J Hypertens. 1997;15:613–618
  36. Hayakawa H, Coffee K, Raij L. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy. Circulation. 1997;96:2407–2413
  37. Keaton AK, White CR, Berecek KH. Captopril treatment and its withdrawal prevents impairment of endothelium-dependent responses in the spontaneously hypertensive rat. Clin Exp Hypertens. 1998;20:847–866
  38. Panza JA, Quyyumi AA, Callahan TS, Epstein SE. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol. 1993;21:1145–1151
  39. Creager MA, Roddy MA. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension. 1994;24:499–505
  40. Taddei S, Virdis A, Ghiadoni L, Mattei P, Salvetti A. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. J Hypertens. 1998;16:447–456
  41. Millgard J, Hagg A, Sarabi M, Lind L. Captopril, but not nifedipine, improves endothelium-dependent vasodilation in hypertensive patients. J Hum Hypertens. 1998;12:511–516
  42. Perticone F, Ceravolo R, Maio R. Calcium antagonist isradipine improves abnormal endothelium-dependent vasodilation in never treated hypertensive patients [see comments]. Cardiovasc Res. 1999;41:299–306
  43. Lyons D, Webster J, Benjamin N. The effect of antihypertensive therapy on responsiveness to local intra-arterial NG-monomethyl-L-arginine in patients with essential hypertension. J Hypertens. 1994;12:1047–1052
  44. JAMA. 1982;247:633–638
  45. Lancet. 1980;1:1261–1267
  46. JAMA. 1970;213:1143–1152
  47. Millgard J, Lind L. Acute hypertension impairs endothelium-dependent vasodilation [see comments]. Clin Sci (Colch). 1998;94:601–607
  48. Bouloumie A, Bauersachs J, Linz W. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension. 1997;30:934–941
  49. Moreau P, Takase H, Kung CF, van Rooijen MM, Schaffner T, Luscher TF. Structure and function of the rat basilar artery during chronic nitric oxide synthase inhibition. Stroke. 1995;26:1922–1928
  50. Bagrov AY, Fedorova OV, Dmitrieva RI, French AW, Anderson DE. Plasma marinobufagenin-like and ouabain-like immunoreactivity during saline volume expansion in anesthetized dogs. Cardiovasc Res. 1996;31:296–305
  51. Yuan C, Manunta P, Chen S, Hamlyn JM, Haddy FJ, Pamnani MB. Role of ouabain-like factors in hypertension: effects of ouabain and certain endogenous ouabain-like factors in hypertension. J Cardiovasc Pharmacol. 1993;22:S10–S12
  52. Kolbel F, Schreiber V. The endogenous digitalis-like factor. Mol Cell Biochem. 1996;160–161:111–115
  53. Woolfson RG, Graves J, LaBella FS, Templeton JF, Poston L. Effect of bufalin and pregnanes on vasoreactivity of human resistance arteries. Biochem Biophys Res Commun. 1992;186:1–7
  54. McCarty MF. Endothelial membrane potential regulates production of both nitric oxide and superoxide – a fundamental determinant of vascular health. Med Hypotheses. 1999;53:277–289
  55. Rubanyi GM. Ionic mechanisms involved in the flow- and pressure-sensor function of the endothelium. Z Kardiol. 1991;80:91–94
  56. Ayajiki K, Kindermann M, Hecker M, Fleming I, Busse R. Intracellular pH and tyrosine phosphorylation but not calcium determine shear stress-induced nitric oxide production in native endothelial cells [see comments]. Circ Res. 1996;78:750–758
  57. Fleming I, Hecker M, Busse R. Intracellular alkalinization induced by bradykinin sustains activation of the constitutive nitric oxide synthase in endothelial cells. Circ Res. 1994;74:1220–1226
  58. Blaustein MP, Hamlyn JM. Sodium transport inhibition, cell calcium, and hypertension. The natriuretic hormone/Na+–Ca2+exchange/hypertension hypothesis. Am J Med. 1984;77:45–59
  59. Nishida Y, Ding J, Zhou MS. Role of nitric oxide in vascular hyper-responsiveness to norepinephrine in hypertensive Dahl rats. J Hypertens. 1998;16:1611–1618
  60. Woolfson RG, Poston L. Effect of ouabain on endothelium-dependent relaxation of human resistance arteries. Hypertension. 1991;17:619–625
  61. Alonso MJ, Salaices M, Sanchez-Ferrer CF, Marin J. Predominant role for nitric oxide in the relaxation induced by acetylcholine in cat cerebral arteries. J Pharmacol Exp Ther. 1992;261:12–20
  62. Poston L, Woolfson RG, Graves JE. Effects of sodium-transport inhibition in human resistance arteries. J Cardiovasc Pharmacol. 1993;22:S1–S3
  63. Boegehold MA. Flow-dependent arteriolar dilation in normotensive rats fed low- or high-salt diets. Am J Physiol. 1995;269:H1407–H1414
  64. Tobian L, Hanlon S. High sodium chloride diets injure arteries and raise mortality without changing blood pressure. Hypertension. 1990;15:900–903
  65. Perry IJ, Beevers DG. Salt intake and stroke: a possible direct effect. J Hum Hypertens. 1992;6:23–25
  66. Ikeda M, Kasahara M, Koizumi A, Watanabe T. Correlation of cerebrovascular disease standardized mortality ratios with dietary sodium and the sodium/potassium ratio among the Japanese population. Prev Med. 1986;15:46–59
  67. Cappuccio FP, Markandu ND, Carney C, Sagnella GA, MacGregor GA. Double-blind randomized trial of modest salt restriction in older people [see comments]. Lancet. 1997;350:850–854
  68. Bereta J, Cohen MC, Bereta M. Stimulatory effect of ouabain on VCAM-1 and iNOS expression in murine endothelial cells: involvement of NF-kappa B. FEBS Lett. 1995;377:21–25
  69. Tobian L, Lange J, Ulm K, Wold L, Iwai J. Potassium reduces cerebral hemorrhage and death rate in hypertensive rats, even when blood pressure is not lowered. Hypertension. 1985;7:I110–I114
  70. Sugimoto T, Tobian L, Ganguli MC. High potassium diets protect against dysfunction of endothelial cells in stroke-prone spontaneously hypertensive rats. Hypertension. 1988;11:579–585
  71. Khaw KT, Barrett-Connor E. Dietary potassium and stroke-associated mortality. A 12-year prospective population study. N Engl J Med. 1987;316:235–240
  72. Ascherio A, Rimm EB, Hernan MA. Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US men. Circulation. 1998;98:1198–1204
  73. McCabe RD, Bakarich MA, Srivastava K, Young DB. Potassium inhibits free radical formation. Hypertension. 1994;24:77–82
  74. Yang BC, Li DY, Weng YF, Lynch J, Wingo CS, Mehta JL. Increased superoxide anion generation and altered vasoreactivity in rabbits on low-potassium diet. Am J Physiol. 1998;274:H1955–H1961
  75. Raij L, Luscher TF, Vanhoutte PM. High potassium diet augments endothelium-dependent relaxations in the Dahl rat. Hypertension. 1988;12:562–567
  76. Taddei S, Mattei P, Virdis A, Sudano I, Ghiadoni L, Salvetti A. Effect of potassium on vasodilation to acetylcholine in essential hypertension. Hypertension. 1994;23:485–490
  77. Meneely GR, Battarbee HD. High sodium-low potassium environment and hypertension. Am J Cardiol. 1976;38:768–785
  78. Lindeberg S, Lundh B. Apparent absence of stroke and ischaemic heart disease in a traditional Melanesian island: a clinical study in Kitava. J Intern Med. 1993;233:269–275
  79. Lindeberg S, Berntorp E, Nilsson-Ehle P, Terent A, Vessby B. Age relations of cardiovascular risk factors in a traditional Melanesian society: the Kitava Study. Am J Clin Nutr. 1997;66:845–852
  80. Trowell HC. Hypertension, obesity, diabetes mellitus and coronary heart disease. In:  Trowell HC,  Burkitt DP editor. Western Diseases: Their Emergence and Prevention. Cambridge, MA: Harvard University Press; 1981;p. 3–32
  81. Tobian L, Jahner TM, Johnson MA. Atherosclerotic cholesterol ester deposition is markedly reduced with a high-potassium diet. J Hypertens. 1989;7:S244–S245
  82. Ma G, Young DB, Clower BR. Inverse relationship between potassium intake and coronary artery disease in the cholesterol-fed rabbit [In Process Citation]. Am J Hypertens. 1999;12:821–825
  83. Yamaguchi Y, Kitagawa S, Kwon Y, Shinozuka K, Kunitomo M. Different cholesterol deposition in aorta of Dahl salt-sensitive rats and spontaneously hypertensive rats fed a high-cholesterol diet. Clin Exp Pharmacol Physiol. 1995;22:S249–S250
  84. Young DB, Lin H, McCabe RD. Potassium’s cardiovascular protective mechanisms. Am J Physiol. 1995;268:R825–R837
  85. Leung SW, Teoh H, Quan A, Man RY. Endothelial dysfunction exacerbates the impairment of relaxation by lysophosphatidylcholine in porcine coronary artery. Clin Exp Pharmacol Physiol. 1997;24:984–986
  86. Noguchi T, Sasaki Y, Seki J, Giddings JC, Yamamoto J. Effects of voluntary exercise and L-arginine on thrombogenesis and microcirculation in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1999;26:330–335
  87. Cooke JP. Is atherosclerosis an arginine deficiency disease?. J Investig Med. 1998;46:377–380
  88. Wascher TC, Posch K, Wallner S, Hermetter A, Kostner GM, Graier WF. Vascular effects of L-arginine: anything beyond a substrate for the NO- synthase?. Biochem Biophys Res Commun. 1997;234:35–38
  89. Boger RH, Bode-Boger SM, Szuba A. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98:1842–1847
  90. Surdacki A, Nowicki M, Sandmann J. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol. 1999;33:652–658
  91. Miyazaki H, Matsuoka H, Cooke JP. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999;99:1141–1146
  92. Panza JA, Casino PR, Badar DM, Quyyumi AA. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension [see comments]. Circulation. 1993;87:1475–1481
  93. Boger RH, Bode-Boger SM, Thiele W, Creutzig A, Alexander K, Frolich JC. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol. 1998;32:1336–1344
  94. Rector TS, Bank AJ, Mullen KA. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure [see comments]. Circulation. 1996;93:2135–2141
  95. Candipan RC, Wang BY, Buitrago R, Tsao PS, Cooke JP. Regression or progression. Dependency on vascular nitric oxide. Arterioscler Thromb Vasc Biol. 1996;16:44–50
  96. Boger RH, Bode-Boger SM, Brandes RP. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation. 1997;96:1282–1290
  97. Zhang J, Sasaki S, Amano K, Kesteloot H. Fish consumption and mortality from all causes, ischemic heart disease, and stroke: an ecological study. Prev Med. 1999;28:520–529
  98. Gillum RF, Mussolino ME, Madans JH. The relationship between fish consumption and stroke incidence. The NHANES I Epidemiologic Follow-up Study (National Health and Nutrition Examination Survey). Arch Intern Med. 1996;156:537–542
  99. Keli SO, Feskens EJ, Kromhout D. Fish consumption and risk of stroke. The Zutphen Study. Stroke. 1994;25:328–332
  100. Fleischhauer FJ, Yan WD, Fischell TA. Fish oil improves endothelium-dependent coronary vasodilation in heart transplant recipients. J Am Coll Cardiol. 1993;21:982–989
  101. Tagawa H, Shimokawa H, Tagawa T, Kuroiwa-Matsumoto M, Hirooka Y, Takeshita A. Long-term treatment with eicosapentaenoic acid augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilation in patients with coronary artery disease. J Cardiovasc Pharmacol. 1999;33:633–640
  102. Yin K, Croft KD, Beilin LJ. Effect of pure eicosapentaenoic acid feeding on blood pressure and vascular reactivity in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1988;15:275–280
  103. Shimokawa H, Vanhoutte PM. Dietary cod-liver oil improves endothelium-dependent responses in hypercholesterolemic and atherosclerotic porcine coronary arteries. Circulation. 1988;78:1421–1430
  104. Yin K, Chu ZM, Beilin LJ. Blood pressure and vascular reactivity changes in spontaneously hypertensive rats fed fish oil. Br J Pharmacol. 1991;102:991–997
  105. Murakami T, Ogawa H, Hayashi M, Yoshizumi H. Suppressive action of docosahexaenoic acid enriched-Euglena on reduction of endothelium-dependent relaxation in stroke-prone spontaneously hypertensive rats (SHRSP). J Nutr Sci Vitaminol (Tokyo). 1997;43:211–223
  106. Katayama Y, Katsumata T, Muramatsu H, Usuda K, Obo R, Terashi A. Effect of long-term administration of ethyl eicosapentate (EPA-E) on local cerebral blood flow and glucose utilization in stroke-prone spontaneously hypertensive rats (SHRSP). Brain Res. 1997;761:300–305
  107. Minami M, Kimura S, Endo T. Effects of dietary docosahexaenoic acid on survival time and stroke-related behavior in stroke-prone spontaneously hypertensive rats. Gen Pharmacol. 1997;29:401–407
  108. Whitaker MO, Needleman P, Wyche A, Fitzpatrick FA, Sprecher H. PGD3 is the mediator of the antiaggregatory effects of the trienoic endoperoxide PGH3. Adv Prostaglandin Thromboxane Res. 1980;6:301–303
  109. Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development [see comments]. Am J Clin Nutr. 1991;54:438–463
  110. Lu X, Liu SY, Man RY. Enhancement of endothelium dependent relaxation in the rat aortic ring by selenium supplement. Cardiovasc Res. 1994;28:345–348
  111. McCarty MF. Oxidants downstream from superoxide inhibit nitric oxide production by vascular endothelium – a key role for selenium-dependent enzymes in vascular health. Medical Hypotheses. 1999;
  112. Virtamo J, Valkeila E, Alfthan G, Punsar S, Huttunen JK, Karvonen MJ. Serum selenium and the risk of coronary heart disease and stroke. Am J Epidemiol. 1985;122:276–282
  113. Salvini S, Hennekens CH, Morris JS, Willett WC, Stampfer MJ. Plasma levels of the antioxidant selenium and risk of myocardial infarction among U.S. physicians. Am J Cardiol. 1995;76:1218–1221
  114. Mark SD, Wang W, Fraumeni JFJ. Do nutritional supplements lower the risk of stroke or hypertension? [comment]. Epidemiology. 1998;9:9–15
  115. Upchurch GRJ, Welch GN, Fabian AJ. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 1997;272:17012–17017
  116. Danysz A, Oledzka K, Bukowska-Kiliszek M. Influence of coenzyme Q-10 on the hypotensive effects of enalapril and nitrendipine in spontaneously hypertensive rats. Pol J Pharmacol. 1994;46:457–461
  117. Igarashi T, Nakajima Y, Tanaka M, Otake S. Effect of coenzyme Q10 on experimental hypertension in rats and dogs. J Pharmacol Exp Ther. 1974;189:149–156
  118. Yamagami T, Iwamoto Y, Folkers K, Blomqvist CG. Reduction by coenzyme Q10 of hypertension induced by deoxycorticosterone and saline in rats. Int J Vitam Nutr Res. 1974;44:487–496
  119. Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Hum Hypertens. 1999;13:203–208
  120. Langsjoen P, Willis R, Folkers K. Treatment of essential hypertension with coenzyme Q10. Mol Aspects Med. 1994;15:S265–S272
  121. Digiesi V, Cantini F, Oradei A. Coenzyme Q10 in essential hypertension. Mol Aspects Med. 1994;15:s257–s263
  122. Whitman GJ, Niibori K, Yokoyama H, Crestanello JA, Lingle DM, Momeni R. The mechanisms of coenzyme Q10 as therapy for myocardial ischemia reperfusion injury. Mol Aspects Med. 1997;18:S195–S203
  123. Ogawa N, Tsukamoto S, Hirose Y, Kuroda H. Survival effect of coenzyme Q10 and naloxone on experimental stroke gerbils. Pharmacol Biochem Behav. 1986;24:315–317
  124. Grieb P, Ryba MS, Sawicki J, Chrapusta SJ. Oral coenzyme Q10 administration prevents the development of ischemic brain lesions in a rabbit model of symptomatic vasospasm. Acta Neuropathol (Berl). 1997;94:363–368
  125. Danysz A, Oledzka K, Bukowska-Kiliszek M. Influence of coenzyme Q-10 on the hypotensive effects of enalapril and nitrendipine in spontaneously hypertensive rats. Pol J Pharmacol. 1994;46:457–461
  126. Serebruany VL, Gurbel PA, Ordonez JV. Could coenzyme Q10 affect hemostasis by inhibiting platelet vitronectin (CD51/CD61) receptor?. Mol Aspects Med. 1997;18:S189–S194
  127. Paffenbarger RSJ, Wing AL. Characteristics in youth predisposing to fatal stroke in later years. Lancet. 1967;1:753–754
  128. Herman B, Leyten AC, van Luijk JH, Frenken CW, Op dCA, Schulte BP. An evaluation of risk factors for stroke in a Dutch community. Stroke. 1982;13:334–339
  129. Sacco RL, Gan R, Boden-Albala B. Leisure-time physical activity and ischemic stroke risk: the Northern Manhattan Stroke Study. Stroke. 1998;29:380–387
  130. Lee IM, Hennekens CH, Berger K, Buring JE, Manson JE. Exercise and risk of stroke in male physicians. Stroke. 1999;30:1–6
  131. Agnarsson U, Thorgeirsson G, Sigvaldason H, Sigfusson N. Effects of leisure-time physical activity and ventilatory function on risk for stroke in men: the Reykjavik Study. Ann Intern Med. 1999;130:987–990
  132. Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res. 1994;74:349–353
  133. Laughlin MH. Endothelium-mediated control of coronary vascular tone after chronic exercise training. Med Sci Sports Exerc. 1995;27:1135–1144
  134. Delp MD, Laughlin MH. Time course of enhanced endothelium-mediated dilation in aorta of trained rats. Med Sci Sports Exerc. 1997;29:1454–1461
  135. Woodman CR, Muller JM, Laughlin MH, Price EM. Introduction of nitric oxide synthase mRNA in coronary resistance arteries isolated from exercise-trained pigs. Am J Physiol. 1997;273:H2575–H2579
  136. Varin R, Mulder P, Richard V. Exercise improves flow-mediated vasodilatation of skeletal muscle arteries in rats with chronic heart failure. Role of nitric oxide, prostanoids, and oxidant stress. Circulation. 1999;99:2951–2957
  137. Jensen-Urstad K, Bouvier F, Jensen-Urstad M. Preserved vascular reactivity in elderly male athletes. Scand J Med Sci Sports. 1999;9:88–91
  138. Clarkson P, Montgomery HE, Mullen MJ. Exercise training enhances endothelial function in young men. J Am Coll Cardiol. 1999;33:1379–1385
  139. Hambrecht R, Fiehn E, Weigl C. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation. 1998;98:2709–2715
  140. Katz SD, Yuen J, Bijou R, LeJemtel TH. Training improves endothelium-dependent vasodilation in resistance vessels of patients with heart failure. J Appl Physiol. 1997;82:1488–1492
  141. MacRitchie AN, Jun SS, Chen Z. Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium. Circ Res. 1997;81:355–362
  142. Hayashi T, Yamada K, Esaki T. Estrogen increases endothelial nitric oxide by a receptor-mediated system. Biochem Biophys Res Commun. 1995;214:847–855
  143. Kleinert H, Wallerath T, Euchenhofer C, Ihrig-Biedert I, Li H, Forstermann U. Estrogens increase transcription of the human endothelial NO synthase gene: analysis of the transcription factors involved. Hypertension. 1998;31:582–588
  144. Goetz RM, Morano I, Calovini T, Studer R, Holtz J. Increased expression of endothelial constitutive nitric oxide synthase in rat aorta during pregnancy. Biochem Biophys Res Commun. 1994;205:905–910
  145. Shaul PW. Rapid activation of endothelial nitric oxide synthase by estrogen. Steroids. 1999;64:28–34
  146. Kirsch EA, Yuhanna IS, Chen Z, German Z, Sherman TS, Shaul PW. Estrogen acutely stimulates endothelial nitric oxide synthase in H441 human airway epithelial cells. Am J Respir Cell Mol Biol. 1999;20:658–666
  147. Goetz RM, Thatte HS, Prabhakar P, Cho MR, Michel T, Golan DE. Estradiol induces the calcium-dependent translocation of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1999;96:2788–2793
  148. Koh KK, Cardillo C, Bui MN. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation. 1999;99:354–360
  149. Lekakis J, Papamichael C, Mavrikakis M, Voutsas A, Stamatelopoulos S. Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud’s phenomenon secondary to systemic sclerosis. Am J Cardiol. 1998;82:1555, 7, A8
  150. Gerhard M, Walsh BW, Tawakol A. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation. 1998;98:1158–1163
  151. Arora S, Veves A, Caballaro AE, Smakowski P, LoGerfo FW. Estrogen improves endothelial function. J Vasc Surg. 1998;27:1141–1146
  152. Tagawa H, Shimokawa H, Tagawa T, Kuroiwa-Matsumoto M, Hirooka Y, Takeshita A. Short-term estrogen augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilation in postmenopausal women. J Cardiovasc Pharmacol. 1997;30:481–488
  153. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ. 1988;297:519–522
  154. Hillard TC, Whitcroft S, Ellerington MC, Whitehead MI. The long-term risks and benefits of hormone replacement therapy. J Clin Pharm Ther. 1991;16:231–245
  155. Sato Y, Nakatsuka H, Watanabe T. Possible contribution of green tea drinking habits to the prevention of stroke. Tohoku J Exp Med. 1989;157:337–343
  156. Uchida S, Ozaki M, Akashi T, Yamashita K, Niwa M, Taniyama K. Effects of (-)- epigallocatechin-3-O-gallate (green tea tannin) on the life span of stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1995;22:S302–S303
  157. Ascherio A, Rimm EB, Hernan MA. Relation of consumption of vitamin E, vitamin C, and carotenoids to risk for stroke among men in the United States. Ann Intern Med. 1999;130:963–970
  158. Keli SO, Hertog MG, Feskens EJ, Kromhout D. Dietary flavonoids, antioxidant vitamins, and incidence of stroke: the Zutphen study. Arch Intern Med. 1996;156:637–642
  159. Hertog MG, Sweetnam PM, Fehily AM, Elwood PC, Kromhout D. Antioxidant flavonols and ischemic heart disease in a Welsh population of men: the Caerphilly Study. Am J Clin Nutr. 1997;65:1489–1494
  160. Ramasamy S, Drummond GR, Ahn J. Modulation of expression of endothelial nitric oxide synthase by nordihydroguaiaretic acid, a phenolic antioxidant in cultured endothelial cells. Mol Pharmacol. 1999;56:116–123
  161. Yu R, Jiao JJ, Duh JL, Gudehithlu K, Tan TH, Kong AN. Activation of mitogen-activated protein kinases by green tea polyphenols: potential signaling pathways in the regulation of antioxidant-responsive element-mediated phase II enzyme gene expression. Carcinogenesis. 1997;18:451–456
  162. Talalay P, Fahey JW, Holtzclaw WD, Prestera T, Zhang Y. Chemoprotection against cancer by phase 2 enzyme induction. Toxicol Lett. 1995;82–83:173–179
  163. Joshipura KJ, Ascherio A, Manson JE. Fruit and vegetable intake in relation to risk of ischemic stroke. JAMA. 1999;282:1233–1239
  164. Honore EK, Williams JK, Anthony MS, Clarkson TB. Soy isoflavones enhance coronary vascular reactivity in atherosclerotic female macaques. Fertil Steril. 1997;67:148–154
  165. Wang W, Liu LQ, Higuchi CM, Chen H. Induction of NADPH:quinone reductase by dietary phytoestrogens in colonic Colo205 cells. Biochem Pharmacol. 1998;56:189–195
  166. Suschek C, Kolb H, Kolb-Bachofen V. Dobesilate enhances endothelial nitric oxide synthase-activity in macro- and microvascular endothelial cells. Br J Pharmacol. 1997;122:1502–1508
  167. Freese R, Basu S, Hietanen E. Green tea extract decreases plasma malondialdehyde concentration but does not affect other indicators of oxidative stress, nitric oxide production, or hemostatic factors during a high-linoleic acid diet in healthy females [In Process Citation]. Eur J Nutr. 1999;38:149–157
  168. Reed DM. The paradox of high risk of stroke in populations with low risk of coronary heart disease. Am J Epidemiol. 1990;131:579–588
  169. Plehn JF, Davis BR, Sacks FM. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators [see comments]. Circulation. 1999;99:216–223
  170. Endres M, Laufs U, Huang Z. Stroke protection by 3-hydroxy-3-methylglutary (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998;95:8880–8885
  171. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998;273:24266–24271
  172. O’Donnell MP, Kasiske BL, Katz SA, Schmitz PG, Keane WF. Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension. 1992;20:651–658
  173. Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension. 1997;30:968–974
  174. Alvarez DS, Perez-Guerrero C, Herrera MD, Marhuenda E. Effects of chronic treatment with simvastatin on endothelial dysfunction in spontaneously hypertensive rats [In Process Citation]. J Hypertens. 1999;17:769–776
  175. Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993;268:11230–11238
  176. Tomeo AC, Geller M, Watkins TR, Gapor A, Bierenbaum ML. Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis. Lipids. 1995;30:1179–1183
  177. Fuhrman B, Elis A, Aviram M. Hypocholesterolemic effect of lycopene and beta-carotene is related to suppression of cholesterol synthesis and augmentation of LDL receptor activity in macrophages. Biochem Biophys Res Commun. 1997;233:658–662
  178. Suganuma H, Inakuma T. Protective effect of dietary tomato against endothelial dysfunction in hypercholesterolemic mice. Biosci Biotechnol Biochem. 1999;63:78–82
  179. Kohlmeier L, Kark JD, Gomez-Gracia E. Lycopene and myocardial infarction risk in the EURAMIC Study [see comments]. Am J Epidemiol. 1997;146:618–626
  180. Schmidt R, Fazekas F, Hayn M. Risk factors for microangiopathy-related cerebral damage in the Austrian stroke prevention study. J Neurol Sci. 1997;152:15–21
  181. Sacco RL, Roberts JK, Jacobs BS. Homocysteine as a risk factor for ischemic stroke: an epidemiological story in evolution. Neuroepidemiology. 1998;17:167–173
  182. Perry IJ. Homocysteine, hypertension and stroke. J Hum Hypertens. 1999;13:289–293
  183. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation. 1999;99:1156–1160
  184. Bellamy MF, McDowell IF, Ramsey MW. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation. 1998;98:1848–1852
  185. Woo KS, Chook P, Lolin YI. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation. 1997;96:2542–2544
  186. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation. 1997;95:1119–1121
  187. Lentz SR, Sobey CG, Piegors DJ. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia [see comments]. J Clin Invest. 1996;98:24–29
  188. Bellamy MF, IF WM, Ramsey MW, Brownlee M, Newcombe RG, Lewis MJ. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects [In Process Citation]. Eur J Clin Invest. 1999;29:659–662
  189. Folsom AR, Rasmussen ML, Chambless LE. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators [In Process Citation]. Diabetes Care. 1999;22:1077–1083
  190. Lukovits TG, Mazzone TM, Gorelick TM. Diabetes mellitus and cerebrovascular disease. Neuroepidemiology. 1999;18:1–14
  191. Mayhan WG. Impairment of endothelium-dependent dilatation of cerebral arterioles during diabetes mellitus. Am J Physiol. 1989;256:H621–H625
  192. Makimattila S, Virkamaki A, Groop PH. Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus. Circulation. 1996;94:1276–1282
  193. Hogikyan RV, Galecki AT, Pitt B, Halter JB, Greene DA, Supiano MA. Specific impairment of endothelium- dependent vasodilation in subjects with type 2 diabetes independent of obesity. J Clin Endocrinol Metab. 1998;83:1946–1952
  194. Makimattila S, Liu ML, Vakkilainen J. Impaired endothelium-dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants. Diabetes Care. 1999;22:973–981
  195. Williams SB, Goldfine AB, Timimi FK. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation. 1998;97:1695–1701
  196. Kawano H, Motoyama T, Hirashima O. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol. 1999;34:146–154
  197. Mayhan WG, Simmons LK, Sharpe GM. Mechanism of impaired responses of cerebral arterioles during diabetes mellitus. Am J Physiol. 1991;260:H319–H326
  198. Taylor PD, Poston L. The effect of hyperglycaemia on function of rat isolated mesenteric resistance artery. Br J Pharmacol. 1994;113:801–808
  199. Cosentino F, Hishikawa K, Katusic ZS, Luscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation. 1997;96:25–28
  200. Graier WF, Posch K, Wascher TC, Kostner GM. Role of superoxide anions in changes of endothelial vasoactive response during acute hyperglycemia. Horm Metab Res. 1997;29:622–626
  201. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest. 1996;97:2601–2610
  202. Hashimoto M, Akishita M, Eto M. The impairment of flow-mediated vasodilatation in obese men with visceral fat accumulation. Int J Obes Relat Metab Disord. 1998;22:477–484
  203. Steinberg HO, Tarshoby M, Monestel R. Elevated circulating free fatty acid levels impair endothelium- dependent vasodilation. J Clin Invest. 1997;100:1230–1239
  204. Niu XL, Liu LY, Hu ML, Chen X. Some similarities in vascular effects of oleic acid and oxidized low-density lipoproteins on rabbit aorta. J Mol Cell Cardiol. 1995;27:531–539
  205. Egan BM, Hennes MM, Stepniakowski KT, O’Shaughnessy IM, Kissebah AH, Goodfriend TL. Obesity hypertension is related more to insulin’s fatty acid than glucose action. Hypertension. 1996;27:723–728
  206. McCarty MF. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline [In Process Citation]. Med Hypotheses. 1999;52:465–477
  207. Egan BM, Stepniakowski KT. Adverse effects of short-term, very-low-salt diets in subjects with risk-factor clustering. Am J Clin Nutr. 1997;65:671S–677S
  208. Egan BM, Stepniakowski K. Effects of enalapril on the hyperinsulinemic response to severe salt restriction in obese young men with mild systemic hypertension. Am J Cardiol. 1993;72:53–57
  209. de Wardener HE, Kaplan NM. On the assertion that a moderate restriction of sodium intake may have adverse health effects [editorial]. Am J Hypertens. 1993;6:810–814
  210. Bataineh A, Raij L. Angiotensin II, nitric oxide, and end-organ damage in hypertension. Kidney Int. 1998;68:S14–S19
  211. Kenny D, Warltier DC, Pleuss JA, Hoffmann RG, Goodfriend TL, Egan BM. Effect of omega-3 fatty acids on the vascular response to angiotensin in normotensive men. Am J Cardiol. 1992;70:1347–1352
  212. Longworth DL, Drayer JI, Weber MA, Laragh JH. Divergent blood pressure responses during short-term sodium restriction in hypertension. Clin Pharmacol Ther. 1980;27:544–546
  213. Luft FC, Weinberger MH. Heterogeneous responses to changes in dietary salt intake: the salt-sensitivity paradigm. Am J Clin Nutr. 1997;65:612S–617S
  214. Alderman M, Sealey J, Cohen H, Madhavan S, Laragh J. Urinary sodium excretion and myocardial infarction in hypertensive patients: a prospective cohort study. Am J Clin Nutr. 1997;65:682S–686S
  215. Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens. 1997;10:1–8
  216. Sharma AM, Ruland K, Spies KP, Distler A. Salt sensitivity in young normotensive subjects is associated with a hyperinsulinemic response to oral glucose. J Hypertens. 1991;9:329–335
  217. Rocchini AP, Key J, Bondie D. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989;321:580–585
  218. Lind L, Lithell H, Gustafsson IB, Pollare T, Ljunghall S. Metabolic cardiovascular risk factors and sodium sensitivity in hypertensive subjects. Am J Hypertens. 1992;5:502–505
  219. ter Maaten JC, Voordouw JJ, Bakker SJ, Donker AJ, Gans RO. Salt sensitivity correlates positively with insulin sensitivity in healthy volunteers. Eur J Clin Invest. 1999;29:189–195
  220. Haylor J, Singh I, el Nahas AM. Nitric oxide synthesis inhibitor prevents vasodilation by insulin-like growth factor I. Kidney Int. 1991;39:333–335
  221. Copeland KC, Nair KS. Recombinant human insulin-like growth factor-I increases forearm blood flow. J Clin Endocrinol Metab. 1994;79:230–232
  222. Walsh MF, Barazi M, Pete G, Muniyappa R, Dunbar JC, Sowers JR. Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology. 1996;137:1798–1803
  223. Schini-Kerth VB. Dual effects of insulin-like growth factor-I on the constitutive and inducible nitric oxide (NO) synthase-dependent formation of NO in vascular cells [In Process Citation]. J Endocrinol Invest. 1999;22:82–88
  224. Boger RH. Nitric oxide and the mediation of the hemodynamic effects of growth hormone in humans [In Process Citation]. J Endocrinol Invest. 1999;22:75–81
  225. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601–605
  226. Janssen JA, Stolk RP, Pols HA, Grobbee DE, Lamberts SW. Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease [published erratum appears in Arterioscler Thromb Vasc Biol 1998 Jul; 18(7):1197]. Arterioscler Thromb Vasc Biol. 1998;18:277–282
  227. McCarty MF. Vegan proteins may reduce risk for cancer, obesity, and cardiovascular disease by promoting increased glucagon activity. Med Hypotheses. 1999;53:459–485
  228. Horie R, Yamori Y, Nara Y, Sawamura M, Mano M. Effects of sulphur amino acids on the development of hypertension and atherosclerosis in stroke-prone spontaneously hypertensive rats. J Hypertens. 1987;5:S223–S225
  229. Yamori Y, Horie R, Nara Y. Pathogenesis and dietary prevention of cerebrovascular diseases in animal models and epidemiological evidence for the applicability in man. In:  Yamori Y,  Lenfant C editor. Prevention of cardiovascular diseases: an approach to active long life. Amsterdam: Elsevier Science Publishers; 1987;p. 163–177
  230. Mayhan WG, Faraci FM, Baumbach GL, Heistad DD. Effects of aging on responses of cerebral arterioles. Am J Physiol. 1990;258:H1138–H1143
  231. Taddei S, Virdis A, Mattei P. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation. 1995;91:1981–1987
  232. Gerhard M, Roddy MA, Creager SJ, Creager MA. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension. 1996;27:849–853
  233. Faraci FM. Endothelium-derived vasoactive factors and regulation of the cerebral circulation. Neurosurgery. 1993;33:648–658
  234. Shechter M, Merz CN, Paul-Labrador M. Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease. Am J Cardiol. 1999;84:152–156
  235. Kawano Y, Matsuoka H, Takishita S, Omae T. Effects of magnesium supplementation in hypertensive patients: assessment by office, home, and ambulatory blood pressures. Hypertension. 1998;32:260–265
  236. Altura BT, Altura BM. Interactions of Mg and K on cerebral vessels–aspects in view of stroke. Review of present status and new findings. Magnesium. 1984;3:195–211
  237. Hayes KC, Pronczuk A, Addesa AE, Stephan ZF. Taurine modulates platelet aggregation in cats and humans. Am J Clin Nutr. 1989;49:1211–1216
  238. Kohashi N, Katori R. Decrease of urinary taurine in essential hypertension. Jpn Heart J. 1983;24:91–102
  239. Sato Y, Ogata E, Fujita T. Hypotensive action of taurine in DOCA-salt rats–involvement of sympathoadrenal inhibition and endogenous opiate. Jpn Circ J. 1991;55:500–508
  240. Fujita T, Ando K, Noda H, Ito Y, Sato Y. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Circulation. 1987;75:525–532
  241. Li N, Sawamura M, Nara Y, Ikeda K, Yamori Y. Direct inhibitory effects of taurine on norepinephrine-induced contraction in mesenteric artery of stroke-prone spontaneously hypertensive rats. Adv Exp Med Biol. 1996;403:257–262
  242. Yoshimura T, Ito M, Matsui K, Fujisaki S. Effects of highly purified eicosapentaenoic acid on vascular reactivity to angiotensin II and norepinephrine in the rabbit. Prostaglandins. 1986;32:179–188
  243. Altura BM, Weaver C, Gebrewold A, Altura BT, Gupta RK. Continuous osmotic minipump infusion of alcohol into brain decreases brain [Mg2+] and brain bioenergetics and enhances susceptibility to hemorrhagic stroke: an in vivo 31P-NMR study. Alcohol. 1998;15:113–117
  244. Ema M, Gebrewold A, Altura BT, Zhang A, Altura BM. Alcohol-induced vascular damage of brain is ameliorated by administration of magnesium. Alcohol. 1998;15:95–103
  245. Loeper J, Goy-Loeper J, Rozensztajn L, Fragny M. The antiatheromatous action of silicon. Atherosclerosis. 1979;33:397–408
  246. McCarty MF. Reported antiatherosclerotic activity of silicon may reflect increased endothelial synthesis of heparan sulfate proteoglycans. Med Hypotheses. 1997;49:175–176
  247. Okumura K, Iseki K, Wakugami K. Low serum cholesterol as a risk factor for hemorrhagic stroke in men: a community-based mass screening in Okinawa, Japan. Jpn Circ J. 1999;63:53–58
  248. Gillman MW, Cupples LA, Millen BE, Ellison RC, Wolf PA. Inverse association of dietary fat with development of ischemic stroke in men [see comments]. JAMA. 1997;278:2145–2150
  249. Karppanen H. An antihypertensive salt: crucial role of Mildred Seelig in its development. J Am Coll Nutr. 1994;13:493–495
  250. Razay G, Wilcock GK. Hyperinsulinaemia and Alzheimer’s disease. Age Ageing. 1994;23:396–399
  251. Leibson CL, Rocca WA, Hanson VA. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol. 1997;145:301–308
  252. Skoog I, Lernfelt B, Landahl S. 15-year longitudinal study of blood pressure and dementia [see comments]. Lancet. 1996;347:1141–1145
  253. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG. Estrogen replacement therapy in older women. Comparisons between Alzheimer’s disease cases and nondemented control subjects. Arch Neurol. 1994;51:896–900
  254. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer’s disease in women. Am J Epidemiol. 1994;140:256–261
  255. Hofman A, Ott A, Breteler MM. Atherosclerosis, apolipoprotein E., and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study [see comments]. Lancet. 1997;349:151–154
  256. McCarty MF. Vascular nitric oxide may lessen Alzheimer’s risk. Med Hypotheses. 1998;51:465–476
  257. Breteler MM, van Duijn CM, Chandra V. Medical history and the risk of Alzheimer’s disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol. 1991;20:S36–S42
  258. Rocca WA. Frequency, distribution, and risk factors for Alzheimer’s disease. Nurs Clin North Am. 1994;29:101–111
  259. Lekakis J, Papamichael C, Alevizaki M. Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high- normal serum thyrotropin (TSH) values. Thyroid. 1997;7:411–414
  260. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA. 1995;274:1846–1851
  261. Swan GE, DeCarli C, Miller BL. Association of midlife blood pressure to late-life cognitive decline and brain morphology. Neurology. 1998;51:986–993
  262. Elias MF. Effects of chronic hypertension on cognitive functioning. Geriatrics. 1998;53:S49–S52
  263. Forette F, Seux ML, Staessen JA. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial [see comments]. Lancet. 1998;352:1347–1351
  264. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study [see comments]. JAMA. 1997;277:813–817
  265. Paris D, Town T, Parker TA. Inhibition of Alzheimer’s beta-amyloid induced vasoactivity and proinflammatory response in microglia by a cGMP- dependent mechanism. Exp Neurol. 1999;157:211–221
  266. Trowell HC, Burkitt DP. Treatment and prevention: a note on autoimmune disease in sub-Saharal Africans. In:  Trowell HC,  Burkitt DP editor. Western Diseases: Their Emergence and Prevention. Cambridge, MA: Harvard University Press; 1981;p. 436–443
  267. Hendrie HC, Osuntokun BO, Hall KS. Prevalence of Alzheimer’s disease and dementia in two communities: Nigerian Africans and African Americans [see comments]. Am J Psychiatry. 1995;152:1485–1492
  268. Seddon JM, Ajani UA, Sperduto RD. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration.Eye Disease Case-Control Study Group [see comments] [published erratum appears in JAMA 1995 Feb 22;273(8):622]. JAMA. 1994;272:1413–1420
  269. Snodderly DM. Evidence for protection against age- related macular degeneration by carotenoids and antioxidant vitamins. Am J Clin Nutr. 1995;62:1448S–1461S
  270. Arch Ophthalmol. 1992;110:1701–1708
  271. Snow KK, Seddon JM. Do age-related macular degeneration and cardiovascular disease share common antecedents? [In Process Citation]. Ophthalmic Epidemiol. 1999;6:125–143
  272. Chiou GC, Liu SX, Li BH, Chiang CH, Varma RS. Ocular hypotensive effects of L-arginine and its derivatives and their actions on ocular blood flow. J Ocul Pharmacol Ther. 1995;11:1–10
  273. Liu SX, Chiou GC, Varma RS. Improvement of retinal functions after ischemia with L-arginine and its derivatives. J Ocul Pharmacol Ther. 1995;11:261–265
  274. Xuan B, Zhou YH, Varma R, Chiou GC. Effects of some N-nitropyrazole derivatives on ocular blood flow and retinal function recovery after ischemic insult. J Ocul Pharmacol Ther. 1999;15:135–142

PII: S0306-9877(00)91075-2

doi: 10.1054/mehy.2000.1075

Medical Hypotheses
Volume 55, Issue 5 , Pages 386-403 , November 2000

Article Tools